A PHASE Ib/ll, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MUTIPLE IMMUNOTHERAPY -BASED TREATMENT COMBINATIONS IN PATIENTS WITH METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA (MORPHEUS-PANCREATIC CANCER)

Contact:

NCT Number:

Protocol:

AAAR2578

Study Status:

Active/Enrolling

Population:

Adult

Phase:

I/II

The purpose of this study is to learn which treatment works best in patients with pancreatic cancer. The study explores multiple treatment combinations. A study drug called atezolizumab may be combined with other drugs such as cobimetinib, PEGPH20, and BL-8040. Patients may also be assigned to receive standard chemotherapy treatment. We Are Now Open To Enrollment For Wave 2.

Are you Eligible? (Inclusion Criteria)

  • tients must have pancreatic ductal adenocarcinoma that continues to grow
  • despite standard therapy.
  • 2. Patients must be in good physical shape. This means that patients must be
  • able to walk, care for themselves, and do light physical activities such as
  • light housework or office work.
  • 3. This study is for patients age 18 or older

Specialty Area(s)

Pancreatic Cancer

Principal Investigator

Profile Headshot
  • Director of Medical Oncology and Translational Research for The Pancreas Center

Trial Location(s)

CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032